News Releases and Selected Publications

  • Novemeber 11, 2011

    N30 Announces Presentation at the CCFA Fall 2011 Conference
    Boulder, Colo, November 10, 2011 -N30 Pharmaceuticals, LLC (N30 Pharma) today announced that it would present a poster at the CCFA Inflammatory Bowel Diseases 2011 conference in Florida starting December 1, 2011. The title of the poster is "S-Nitrosoglutathione Reductase Inhibitors for the Prevention and Treatment of Experimental Colitis". More...PDF(787Kb)

  • August 28, 2011

    N30 Announces Presentation at the ACS Fall 2011 National Meeting
    Boulder, Colo, August 28, 2011 -N30 Pharmaceuticals, LLC (N30 Pharma) today announced that it would present a poster at the ACS Fall 2011 National Meeting in Denver, CO starting the week of August 28, 2011. The title of the poster is "Structure – Activity Relationships of Pyrrole Based S-Nitrosoglutathione Reductase Inhibitors – Carboxamide Modification". More...PDF(471Kb)

  • July 14, 2011

    N30 Announces Poster Presentation at GRC Summer 2011
    Boulder, Colo, July 7, 2011 -N30 Pharmaceuticals, LLC (N30 Pharma) today announced that it would make a presentation at the Gordon Research Conference in July 2011. The poster title is "Heterozygous Deletion of S-Nitrosoglutathione Reductase in Mice Does Not Increase Nitrosative Inactivation of O6-Alkylguanine-DNA Alkyltransferase or Diethylnitrosamine-induced Hepatocarcinogenesis". More...PDF(261Kb)

  • May 3, 2011

    N30 Announces Poster Presentation at ATS 2011
    Boulder, Colo, May 3, 2011 -N30 Pharmaceuticals, LLC (N30 Pharma) today announced a presentation at the ATS conference in May 2011. The poster title is "Oral S-Nitrosoglutathione Reductase Inhibitors Attenuate Pulmonary Inflammation and Decrease Airspace Enlargement in Experimental Models of COPD". More...PDF(503Kb)

  • March 27, 2011

    N30 Announces Presentation at the ACS Spring 2011 National Meeting & Exposition
    Boulder, Colo, March 27, 2011 -N30 Pharmaceuticals, LLC (N30 Pharma) today announced that it would make a presentation at the ACS Spring 2011 National Meeting & Exposition in Anaheim, CA starting the week of March 27, 2011. The title of the presentation is "Discovery of S-nitrosoglutathione reductase inhibitors as potential agents to treat asthma, COPD and IBD". More...PDF(1.3Mb)

  • March 14, 2011

    N30 Announces Journal of ACS Medicinal Chemistry Letter Publication
    Boulder, Colo, March 14, 2011—N30 Pharmaceuticals LLC (N30 Pharma) today announced publication of a paper titled, "Discovery of S-Nitrosoglutathione Reductase Inhibitors: Potential Agents for the Treatment of Asthma and Other Inflammatory Diseases" in the Journal of ACS Medicinal Chemistry Letter. This paper details the structure-based optimization of potent small molecule inhibitors of the enzyme S-nitrosoglutathione reductase (GSNOR). The report focuses on the lead chemical series which generated N30 N6022, a first in class GSNOR inhibitor currently in Phase 1b/2a trials for the treatment of asthma. More... PDF (22kb)

  • March 8, 2011

    N30 Releases our Society of Toxicology 50th Anniversary Meeting Presentation Poster
    N30 today has made available the presentation poster used at the 2011 Annual Meeting of the Society of Toxicology in Washington, D.C. on Monday, March 7, 2011. More...PDF (176kb)

  • March 2, 2011

    N30 Announces Presentation at the Society of Toxicology 50th Anniversary Meeting
    Boulder, Colo., March 2, 2011 -- N30 Pharmaceuticals, LLC (N30 Pharma) today announced it will present data at the 2011 Annual Meeting of the Society of Toxicology in Washington, D.C. on Monday, March 7, 2011. The data describe the preclinical safety evaluation of small molecule inhibitors of S-nitrosoglutathione reductase (GSNOR), and the lack of apparent mechanism-based toxicities. GSNOR is a critical enzyme in the endogenous nitric oxide pathway, and its activity is thought to be important in human respiratory, gastrointestinal and cardiovascular disease. N30 Pharma’s first GSNOR inhibitor, N6022, is currently in Phase 1b/2a testing. More... PDF (26kb)

  • Sept 8, 2010

    N30 Announces Initiation of Phase 1 Trials of Novel Reductase Inhibitor
    Boulder, Colo., September 8, 2010 --N30 Pharmaceuticals, LLC today announced it has dosed the first human subject with N6022, a first-in-class inhibitor of s-nitrosoglutathione reductase (GSNOR). N6022 is the first GSNOR inhibitor to be administered to human beings. N6022 has the potential to be an important new treatment for acute exacerbations of human diseases, such as asthma, chronic obstructive pulmonary disease (COPD), inflammatory bowel disease (IBD) and other inflammatory conditions. More... PDF (34kb)

  • Aug 9, 2010

    N30 Presentation At 2010 Medicinal Chemistry Gordon Research Conference
    Boulder, Colo., August 9, 2010 --N30 Pharmaceuticals, LLC announced a presentation this week at the 2010 Medicinal Chemistry Gordon Research Conference at Colby-Sawyer College in New Hampshire. The presentation by Xicheng Sun, PhD is entitled “Discovery of S-Nitrosoglutathione Reductase (GSNOR) Inhibitors as Potential Agents to Treat Asthma and Related Diseases.” It describes the structure-activity relationship and pharmacologic properties of N30 Pharma's novel, reversible GSNOR inhibitors. More... PDF (30kb)